Stocks
Intercept Pharmaceuticals Financial Statements (ICPT) |
||||||||||
| Intercept Pharmaceuticalssmart-lab.ru | % | 2018 | 2019 | 2020 | 2021 | 2022 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2019 | 25.02.2020 | 25.02.2021 | 02.03.2022 | 02.03.2023 | 06.11.2023 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 179.8 | 252.0 | 312.7 | 363.5 | 285.7 | 317.7 | |||
| Operating Income, bln rub | -285.5 | -312.4 | -216.6 | -55.8 | -68.2 | -62.3 | ||||
| EBITDA, bln rub | ? | -278.7 | -303.5 | -212.2 | -53.6 | -61.7 | -41.7 | |||
| Net profit, bln rub | ? | -309.2 | -391.1 | -324.2 | -145.0 | 115.2 | -58.6 | |||
| OCF, bln rub | ? | -240.7 | -236.6 | -170.0 | -41.6 | -26.8 | -63.0 | |||
| CAPEX, bln rub | ? | 0.167 | 1.14 | 3.89 | 0.397 | 0.568 | 0.408 | |||
| FCF, bln rub | ? | -240.9 | -237.7 | -173.9 | -42.0 | -27.3 | -62.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 462.8 | 560.2 | 524.0 | 416.1 | 352.9 | 373.1 | ||||
| Cost of production, bln rub | 2.52 | 4.21 | 5.32 | 3.10 | 0.984 | 0.633 | ||||
| R&D, bln rub | 207.3 | 242.8 | 191.5 | 185.3 | 176.6 | 161.2 | ||||
| Interest expenses, bln rub | 30.5 | 41.1 | 48.1 | 54.4 | 21.4 | 9.98 | ||||
| Assets, bln rub | 509.2 | 754.9 | 580.5 | 527.0 | 553.7 | 393.2 | ||||
| Net Assets, bln rub | ? | 19.1 | 51.6 | -166.9 | -184.0 | 93.1 | 71.8 | |||
| Debt, bln rub | 371.3 | 538.5 | 575.5 | 547.2 | 332.7 | 223.9 | ||||
| Cash, bln rub | 436.2 | 657.3 | 477.2 | 429.4 | 490.9 | 322.7 | ||||
| Net debt, bln rub | -64.9 | -118.8 | 98.3 | 117.8 | -158.2 | -98.9 | ||||
| Ordinary share price, rub | 100.8 | 123.9 | 24.7 | 16.3 | 12.4 | 19.0 | ||||
| Number of ordinary shares, mln | 28.5 | 31.7 | 33.0 | 31.9 | 33.8 | 41.8 | ||||
| Market cap, bln rub | 2 869 | 3 923 | 814 | 519 | 418 | 793 | ||||
| EV, bln rub | ? | 2 804 | 3 804 | 913 | 637 | 260 | 694 | |||
| Book value, bln rub | 19 | 52 | -167 | -184 | 93 | 72 | ||||
| EPS, rub | ? | -10.9 | -12.4 | -9.83 | -4.55 | 3.41 | -1.40 | |||
| FCF/share, rub | -8.46 | -7.51 | -5.28 | -1.32 | -0.81 | -1.50 | ||||
| BV/share, rub | 0.67 | 1.63 | -5.06 | -5.77 | 2.75 | 1.72 | ||||
| EBITDA margin, % | ? | -155.0% | -120.5% | -67.9% | -14.7% | -21.6% | -13.1% | |||
| Net margin, % | ? | -172.0% | -155.2% | -103.7% | -39.9% | 40.3% | -18.4% | |||
| FCF yield, % | ? | -8.40% | -6.06% | -21.4% | -8.10% | -6.54% | -7.92% | |||
| ROE, % | ? | -1 617% | -758.5% | 194.3% | 78.8% | 123.7% | -81.6% | |||
| ROA, % | ? | -60.7% | -51.8% | -55.9% | -27.5% | 20.8% | -14.9% | |||
| P/E | ? | -9.28 | -10.0 | -2.51 | -3.58 | 3.63 | -13.5 | |||
| P/FCF | -11.9 | -16.5 | -4.68 | -12.3 | -15.3 | -12.6 | ||||
| P/S | ? | 16.0 | 15.6 | 2.60 | 1.43 | 1.46 | 2.50 | |||
| P/BV | ? | 150.0 | 76.1 | -4.88 | -2.82 | 4.49 | 11.0 | |||
| EV/EBITDA | ? | -10.1 | -12.5 | -4.30 | -11.9 | -4.22 | -16.7 | |||
| Debt/EBITDA | 0.23 | 0.39 | -0.46 | -2.20 | 2.56 | 2.37 | ||||
| R&D/CAPEX, % | 124 132% | 21 373% | 4 921% | 46 668% | 31 098% | 39 513% | ||||
| CAPEX/Revenue, % | 0.09% | 0.45% | 1.24% | 0.11% | 0.20% | 0.13% | ||||
| Intercept Pharmaceuticals shareholders | ||||||||||
